arrow
U

Ugonma Chukwueke

Harvard University
H指数:26
被引数:3,101

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma
2025-12-150
PRE
CTIM-12. DUAL IMMUNE CHECKPOINT BLOCKADE FOR SURGICALLY ACCESSIBLE RECURRENT GLIOBLASTOMA: CLINICAL AND MOLECULAR OUTCOMES

CTIM-12. 双免疫检查点阻断治疗可手术切除的复发性胶质母细胞瘤:临床与分子结局

2025-11-110
OA
NCOG-43. Clinical outcomes in patients with molecular vs histological glioblastoma

NCOG-43. 分子型与组织学型胶质母细胞瘤患者的临床结局

2025-11-110
OA
SAFETY AND TOLERABILITY OF OLAPARIB, TEMOZOLOMIDE, AND PEMBROLIZUMAB IN A PHASE 2 TRIAL IN PATIENTS WITH PROGRESSIVE GLIOBLASTOMA

奥拉帕利、替莫唑胺和帕博利珠单抗在进展性胶质母细胞瘤患者中的II期试验的安全性与耐受性

2025-11-010
OAAI
DEFICITS IN GAIT QUANTIFIED BY LARGE LANGUAGE MODEL-DERIVED NANO SCORES PREDICT SURVIVAL IN HIGH-GRADE GLIOMA

由大型语言模型衍生的Nano评分量化的步态缺陷预测高级别胶质瘤的生存率

2025-11-010
OAAI
Prognostic significance of contrast enhancement in newly diagnosed grade 2IDH-mutant glioma

对比增强在 newly diagnosed grade 2 IDH-mutant glioma 中的预后意义

2025-11-010
PRE
Impact of distance traveled for clinical trial participation on clinical outcomes in patients with glioblastoma

患者参与临床试验的旅行距离对胶质母细胞瘤患者临床结局的影响

2025-11-010
OAAI
A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell Lymphoma

同步系统性及中枢神经系统弥漫大B细胞淋巴瘤的治疗与预后回顾性研究

2025-11-010
OAAI
Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4

新诊断的IDH突变型WHO 4级星形细胞瘤的预后临床、分子和放射学预测因子

2025-07-010
PRE
Response Assessment in Neuro-Oncology (RANO) 2009-2025: Broad scope and implementation-A progress report

神经肿瘤学反应评估(RANO)2009–2025:广泛范围与实施——进展报告

2025-06-012
PRE
Predicting therapeutic clinical trial enrollment for adult patients with low- and high-grade glioma using supervised machine learning

使用监督式机器学习预测低级别和高级别胶质瘤成年患者的治疗性临床试验入组

2025-01-010
OA
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomes

伊沃西尼布治疗IDH1-mutant胶质瘤,2-4级: 耐受性,反应预测因子和结果

2024-12-191
OAAI
SAFETY LEAD-IN RESULTS FOR QBS10072S IN THE INDIVIDUAL SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT) TRIAL, A RANDOMIZED ADAPTIVE PLATFORM TRIAL FOR NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA
2024-11-110
PRE
CLINICAL AND RADIOGRAPHIC PREDICTORS OF PROGNOSIS IN ASTROCYTOMA, IDH-MUTANT, WHO GRADE 4
2024-11-110
PRE
REAL WORLD EXPERIENCE USING THE IDH INHIBITOR IVOSIDENIB IN IDH MUTANT GLIOMA: TOLERABILITY AND OUTCOMES
2024-11-110
PRE
NEOADJUVANT ANTI-PD1 IMMUNOTHERAPY FOR SURGICALLY ACCESSIBLE RECURRENT GLIOBLASTOMA: CLINICAL AND MOLECULAR OUTCOMES OF A STAGE 2 SINGLE-ARM EXPANSION COHORT
2024-11-110
PRE